NeuroPace, Inc.
NPCENeuroPace, Inc. in brief
NeuroPace, Inc. is a listed company in the Medical Devices industry, based in Mountain View, California, USA. It was founded in 1997. Its market value was $487 M on 18 September 2026, which makes it the 12,666th largest listed company in the world and the 2,552nd largest in the USA on this site. In the year to December 2025 it had sales of $100 M and a net loss of $21 M. It employs about 209 people and Joel Becker is its chief executive. Its shares trade under the symbol NPCE (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About NeuroPace, Inc.
We are a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. By continuously monitoring and analyzing the brain’s electrical activity, recognizing patient-specific abnormal electrical patterns, and responding in real time with imperceptible electrical pulses to prevent seizures, our RNS System is programmed by clinicians to deliver the precise amount of therapy when and where it is needed and provides exceptional clinical outcomes with approximately three minutes of stimulation on average per day. Our RNS System is also the only commercially available device that records continuous brain activity data and allows clinicians to monitor patients not only in person, but also remotely, providing them the data they need to make more informed treatment decisions, thus optimizing patient care. We believe the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment. As of December 31, 2025, over 8,000 patients have received our RNS System. We believe our compelling body of long-term clinical data, demonstrating continuous improvement in outcomes over time, will support the continued adoption of our RNS System among the approximately 575,000 adults in the United States with drug-resistant focal epilepsy. We continue seeking indication expansion to, over time, cover the entire approximately 1.2 million drug-resistant epilepsy patients in the United States and may additionally seek to expand our operations to reach the approximately 16.5 million drug-resistant epilepsy patients globally.
From the company's annual report filed with the US SEC: read the report
NeuroPace, Inc. timeline
- 1997
- 🏁· approximateFounded
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 23 April 2021; shares registered for exchange trading on 14 April 2021.
- 2025
- 💰Record revenue of $100 millionFY2025, the highest of the 6 years on record.
Events of NeuroPace, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,664 (Jan 2022) · #5,023 (Dec 2022) · #4,195 (Jul 2023) · #2,962 (Jan 2024) · #1,267 (Mar 2026) · #2,532 (Aug 2026) · #2,547 (Sep 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 4.8×
- Price / book
- 25.6×
- Free cash flow yield
- -2.3%
- Net margin (TTM)
- -18.4%
- Operating margin
- -16.3%
- Return on equity
- -99.4%
- Liabilities / assets
- 82.0%
- Net debt
- $37M
- Revenue growth
- +25.1%
- R&D / revenue
- 27.9%
- Revenue per employee
- $478 K
- Profit per employee
- $-103 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $100M | +25.1% | $-16M | $-21M | -21.5% |
| Dec 2024 | $80M | +22.1% | $-22M | $-27M | -34.0% |
| Dec 2023 | $65M | +43.7% | $-27M | $-33M | -50.4% |
| Dec 2022 | $46M | +0.8% | $-41M | $-47M | -103.4% |
| Dec 2021 | $45M | +9.8% | $-24M | $-36M | -79.9% |
| Dec 2020 | $41M | — | $-13M | $-24M | -59.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-11M | $0M | $-11M | $-0.66 | $0.00 |
| Dec 2024 | $-18M | $0M | $-18M | $-0.93 | $0.00 |
| Dec 2023 | $-20M | $0M | $-20M | $-1.27 | $0.00 |
| Dec 2022 | $-37M | $1M | $-37M | $-1.91 | — |
| Dec 2021 | $-25M | $0M | $-25M | $-2.17 | — |
| Dec 2020 | $-22M | $0M | $-22M | $-117.85 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $23M (-1.1% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 28, 20268-KCurrent reportRegulation FD disclosure
- Jun 8, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 21, 2026DEF 14AProxy statement
- Mar 3, 202610-KAnnual report · period to Dec 2025
- Mar 3, 20268-KCurrent reportResults of operations
- Nov 4, 202510-QQuarterly report · period to Sep 2025
Official filings of NeuroPace, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $100 M
- Operating income
- $-16 M
- Net income
- $-21 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $106 M
- Total liabilities
- $87 M
- Total equity
- $19 M
As of December-2025
Top 100 institutional investors in NeuroPace, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 3,983,577 | +1,122,410 (+39.23%) | 11.56% | $55 M | Nov 16, 2026 |
| 2 | Polar Capital Holdings Plc | 3,298,104 | 0 (0.00%) | 9.57% | $45 M | Nov 16, 2026 |
| 3 | Soleus Capital Management, L.P. | 3,218,000 | +306,878 (+10.54%) | 9.34% | $44 M | Nov 16, 2026 |
| 4 | Morgan Stanley | 2,568,872 | -85,519 (-3.22%) | 7.46% | $35 M | Nov 13, 2026 |
| 5 | BlackRock, Inc. | 2,467,499 | -10,104 (-0.41%) | 7.16% | $34 M | Nov 13, 2026 |
| 6 | Driehaus Capital Management LLC | 1,429,439 | -17,952 (-1.24%) | 4.15% | $20 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 1,234,175 | +7,103 (+0.58%) | 3.58% | $17 M | Nov 13, 2026 |
| 8 | Orbimed Advisors LLC | 1,055,125 | -450,000 (-29.90%) | 3.06% | $15 M | Nov 16, 2026 |
| 9 | Deutsche Bank AG\ | 935,652 | -3,267 (-0.35%) | 2.72% | $13 M | Nov 6, 2026 |
| 10 | Armistice Capital, LLC | 800,000 | +108,000 (+15.61%) | 2.32% | $11 M | Nov 16, 2026 |
| 11 | Geode Capital Management, LLC | 662,187 | -4,113 (-0.62%) | 1.92% | $9 M | Nov 6, 2026 |
| 12 | State Street Corp | 566,654 | +16,522 (+3.00%) | 1.64% | $8 M | Nov 12, 2026 |
| 13 | Silvercrest Asset Management Group LLC | 314,454 | -29,670 (-8.62%) | 0.91% | $4 M | Nov 16, 2026 |
| 14 | Qube Research & Technologies Ltd | 303,591 | +82,354 (+37.22%) | 0.88% | $4 M | Nov 13, 2026 |
| 15 | D. E. Shaw & Co., Inc. | 263,276 | +102,195 (+63.44%) | 0.76% | $4 M | Nov 16, 2026 |
| 16 | Northern Trust Corp | 259,039 | -986 (-0.38%) | 0.75% | $4 M | Nov 16, 2026 |
| 17 | Citadel Advisors LLC | 247,158 | +118,358 (+91.89%) | 0.72% | $3 M | Nov 16, 2026 |
| 18 | Vanguard Portfolio Management LLC | 223,522 | +3,151 (+1.43%) | 0.65% | $3 M | Nov 13, 2026 |
| 19 | Essex Investment Management Co LLC | 202,202 | -6,501 (-3.11%) | 0.59% | $3 M | Oct 19, 2026 |
| 20 | Vanguard Fiduciary Trust Co | 192,471 | +9,937 (+5.44%) | 0.56% | $3 M | Nov 13, 2026 |
| 21 | Bank Of America Corp /de/ | 179,981 | +159,732 (+788.84%) | 0.52% | $2 M | Nov 16, 2026 |
| 22 | Palumbo Wealth Management LLC | 167,945 | -41,254 (-19.72%) | 0.49% | $2 M | Nov 13, 2026 |
| 23 | Algert Global LLC | 164,516 | -20,258 (-10.96%) | 0.48% | $2 M | Nov 17, 2026 |
| 24 | HighMark Wealth Management LLC | 163,000 | 0 (0.00%) | 0.47% | $2 M | Nov 17, 2026 |
| 25 | Jpmorgan Chase & Co | 154,231 | -19,080 (-11.01%) | 0.45% | $2 M | Nov 12, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Tudor Investment Corp Et Al | 143,233 | +33,359 (+30.36%) | 0.42% | $2 M | Nov 16, 2026 |
| 27 | Goldman Sachs Group Inc | 139,600 | -9,966 (-6.66%) | 0.41% | $2 M | Nov 16, 2026 |
| 28 | Lazard Asset Management LLC | 126,251 | -1,477 (-1.16%) | 0.37% | $2 M | Nov 16, 2026 |
| 29 | Nuveen, LLC | 113,647 | +14,149 (+14.22%) | 0.33% | $2 M | Nov 10, 2026 |
| 30 | BNP Paribas Financial Markets | 86,705 | -972 (-1.11%) | 0.25% | $1 M | Nov 12, 2026 |
| 31 | Charles Schwab Investment Management Inc | 77,879 | +48 (+0.06%) | 0.23% | $1 M | Nov 16, 2026 |
| 32 | XTX Topco Ltd | 67,078 | +46,694 (+229.07%) | 0.19% | $1 M | Nov 16, 2026 |
| 33 | Legato Capital Management LLC | 62,633 | -7,701 (-10.95%) | 0.18% | $1 M | Nov 10, 2026 |
| 34 | Panagora Asset Management Inc | 59,974 | -54,085 (-47.42%) | 0.17% | $1 M | Nov 12, 2026 |
| 35 | Russell Investments Group, Ltd. | 59,197 | -102,967 (-63.50%) | 0.17% | $1 M | Nov 6, 2026 |
| 36 | Bank of New York Mellon Corp | 56,501 | -1,476 (-2.55%) | 0.16% | $1 M | Nov 5, 2026 |
| 37 | Millennium Management LLC | 51,078 | +20,459 (+66.82%) | 0.15% | $1 M | Nov 16, 2026 |
| 38 | Gsa Capital Partners LLP | 44,005 | -71,530 (-61.91%) | 0.13% | $1 M | Nov 16, 2026 |
| 39 | Renaissance Technologies LLC | 43,700 | -67,999 (-60.88%) | 0.13% | $1 M | Nov 12, 2026 |
| 40 | SEI Investments Co | 38,667 | -23,510 (-37.81%) | 0.11% | $1 M | Nov 10, 2026 |
| 41 | Barclays PLC | 37,089 | +6,078 (+19.60%) | 0.11% | $1 M | Nov 6, 2026 |
| 42 | Rhumbline Advisers | 32,110 | +446 (+1.41%) | 0.09% | $0 M | Nov 10, 2026 |
| 43 | AQR Capital Management LLC | 31,944 | -3,976 (-11.07%) | 0.09% | $0 M | Nov 16, 2026 |
| 44 | Squarepoint Ops LLC | 31,511 | +10,246 (+48.18%) | 0.09% | $0 M | Nov 9, 2026 |
| 45 | Point72 Asset Management, L.P. | 28,843 | New | 0.08% | $0 M | Nov 16, 2026 |
| 46 | State Of Wisconsin Investment Board | 26,148 | +10,000 (+61.93%) | 0.08% | $0 M | Nov 16, 2026 |
| 47 | Polar Asset Management Partners Inc. | 25,600 | New | 0.07% | $0 M | Nov 16, 2026 |
| 48 | Quadrature Capital Ltd | 24,402 | New | 0.07% | $0 M | Nov 13, 2026 |
| 49 | Integrated Quantitative Investments LLC | 23,413 | New | 0.07% | $0 M | Nov 13, 2026 |
| 50 | Western Wealth Management, LLC | 22,950 | 0 (0.00%) | 0.07% | $0 M | Nov 9, 2026 |
| 51 | EntryPoint Capital, LLC | 22,850 | +6,357 (+38.54%) | 0.07% | $0 M | Nov 13, 2026 |
| 52 | Price T Rowe Associates Inc /MD/ | 21,764 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 53 | UBS Group AG | 20,320 | +3,786 (+22.90%) | 0.06% | $0 M | Nov 10, 2026 |
| 54 | MetLife Investment Management, LLC | 17,318 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 55 | Quantinno Capital Management LP | 16,834 | +6,601 (+64.51%) | 0.05% | $0 M | Nov 13, 2026 |
| 56 | Susquehanna Portfolio Strategies, LLC | 16,129 | -6,150 (-27.60%) | 0.05% | $0 M | Nov 16, 2026 |
| 57 | FMR LLC | 15,074 | -539,697 (-97.28%) | 0.04% | $0 M | Nov 10, 2026 |
| 58 | Two Sigma Investments, LP | 14,646 | -15,546 (-51.49%) | 0.04% | $0 M | Nov 16, 2026 |
| 59 | Jane Street Group, LLC | 14,271 | -20,167 (-58.56%) | 0.04% | $0 M | Nov 12, 2026 |
| 60 | Invesco Ltd. | 13,907 | -395 (-2.76%) | 0.04% | $0 M | Nov 12, 2026 |
| 61 | Alliancebernstein L.P. | 13,710 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 62 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 12,670 | +466 (+3.82%) | 0.04% | $0 M | Nov 16, 2026 |
| 63 | Wells Fargo & Company/mn | 11,294 | -16,123 (-58.81%) | 0.03% | $0 M | Nov 16, 2026 |
| 64 | Diversified Trust Co | 11,096 | New | 0.03% | $0 M | Nov 6, 2026 |
| 65 | Connor, Clark & Lunn Investment Management Ltd. | 11,093 | -17,599 (-61.34%) | 0.03% | $0 M | Nov 10, 2026 |
| 66 | Entropy Technologies, LP | 10,616 | New | 0.03% | $0 M | Nov 13, 2026 |
| 67 | Vanguard Global Advisers, LLC | 10,091 | +115 (+1.15%) | 0.03% | $0 M | Nov 13, 2026 |
| 68 | Mitsubishi UFJ Asset Management Co., Ltd. | 9,009 | -881 (-8.91%) | 0.03% | $0 M | Nov 5, 2026 |
| 69 | New York State Common Retirement Fund | 7,700 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 70 | Police & Firemen's Retirement System of New Jersey | 6,123 | -3,010 (-32.96%) | 0.02% | $0 M | Nov 9, 2026 |
| 71 | Zurcher Kantonalbank (Zurich Cantonalbank) | 5,839 | New | 0.02% | $0 M | Nov 10, 2026 |
| 72 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3,908 | +3,406 (+678.49%) | 0.01% | $0 M | Nov 16, 2026 |
| 73 | Employees Retirement System of Texas | 3,904 | New | 0.01% | $0 M | Nov 10, 2026 |
| 74 | Tower Research Capital LLC (TRC) | 2,815 | +1,316 (+87.79%) | 0.01% | $0 M | Nov 16, 2026 |
| 75 | Nisa Investment Advisors, LLC | 2,778 | -150 (-5.12%) | 0.01% | $0 M | Oct 20, 2026 |
| 76 | Legal & General Group Plc | 2,586 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 77 | Ameritas Investment Partners, Inc. | 2,455 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 78 | Royal Bank Of Canada | 1,963 | +183 (+10.28%) | 0.01% | $0 M | Nov 16, 2026 |
| 79 | Citigroup Inc | 1,315 | -11,101 (-89.41%) | 0.00% | $0 M | Nov 4, 2026 |
| 80 | Northwestern Mutual Wealth Management Co | 1,200 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 81 | Sterling Capital Management LLC | 869 | +776 (+834.41%) | 0.00% | $0 M | Oct 22, 2026 |
| 82 | Allworth Financial LP | 785 | -722 (-47.91%) | 0.00% | $0 M | Nov 17, 2026 |
| 83 | Steward Partners Investment Advisory, LLC | 505 | +205 (+68.33%) | 0.00% | $0 M | Nov 13, 2026 |
| 84 | Jones Financial Companies Lllp | 376 | +36 (+10.59%) | 0.00% | $0 M | Nov 13, 2026 |
| 85 | California State Teachers Retirement System | 357 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 86 | Arax Advisory Partners | 312 | +190 (+155.74%) | 0.00% | $0 M | Nov 12, 2026 |
| 87 | SJS Investment Consulting Inc. | 84 | +75 (+833.33%) | 0.00% | $0 M | Oct 26, 2026 |
| 88 | Parallel Advisors, LLC | 82 | New | 0.00% | $0 M | Nov 3, 2026 |
| 89 | US Bancorp \de\ | 74 | New | 0.00% | $0 M | Nov 5, 2026 |
| 90 | PNC Financial Services Group, Inc. | 69 | +59 (+590.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 91 | Root Financial Partners, LLC | 63 | New | 0.00% | $0 M | Oct 21, 2026 |
| 92 | Osaic Holdings, Inc. | 44 | -87 (-66.41%) | 0.00% | $0 M | Nov 12, 2026 |
| 93 | Quarry LP | 39 | -122 (-75.78%) | 0.00% | $0 M | Nov 16, 2026 |
| 94 | EverSource Wealth Advisors, LLC | 27 | -23 (-46.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 95 | Rothschild Investment LLC | 25 | -3 (-10.71%) | 0.00% | $0 M | Nov 10, 2026 |
| 96 | SBI Securities Co., Ltd. | 21 | -49 (-70.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 97 | Ascentis Wealth Management, LLC | 18 | New | 0.00% | $0 M | Nov 3, 2026 |
| 98 | Larson Financial Group LLC | 17 | -54 (-76.06%) | 0.00% | $0 M | Nov 5, 2026 |
| 99 | Caitong International Asset Management Co., Ltd | 15 | +12 (+400.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 100 | Simplex Trading, LLC | 12 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding NeuroPace, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 908,479 | $14 M | 2.6% | <0.01% | +9.8% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 688,652 | $11 M | 2.0% | 0.01% | +10% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 290,400 | $5 M | 0.84% | <0.01% | +8.5% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 248,901 | $4 M | 0.72% | 0.03% | +19% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 227,093 | $4 M | 0.66% | 0.07% | −1.2% | May 29, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 288,065 | $4 M | 0.84% | 0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC | 175,099 | $3 M | 0.51% | 0.47% | −1.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 209,986 | $3 M | 0.61% | 0.03% | −42% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 131,045 | $2 M | 0.38% | 0.01% | +3.7% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 126,017 | $2 M | 0.37% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 North Square Dynamic Small Cap FundNorth Square Investments, LLC | 91,663 | $2 M | 0.27% | 0.19% | −3.1% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 89,094 | $1 M | 0.26% | 0.09% | +39% | Jun 30, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 85,121 | $1 M | 0.25% | 0.17% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 108,032 | $1 M | 0.31% | 0.03% | −41% | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 58,053 | $1 M | 0.17% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 64,471 | $1 M | 0.19% | 0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 49,543 | $1 M | 0.14% | 0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 45,638 | $1 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 44,216 | $1 M | 0.13% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 42,655 | $1 M | 0.12% | 0.08% | −7.0% | Jun 30, 2026 |
| 🇺🇸 1290 Essex Small Cap Growth FundEquitable Investment Management, LLC | 50,804 | $1 M | 0.15% | 0.56% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Health Care Equipment ETFSSGA Funds Management, Inc. | 39,657 | $1 M | 0.12% | 0.42% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 37,281 | $1 M | 0.11% | <0.01% | +6.5% | May 31, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 36,286 | $1 M | 0.11% | <0.01% | +10% | May 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 37,644 | $1 M | 0.11% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 29,661 | $0 M | 0.09% | 0.07% | −7.8% | May 31, 2026 |
| 🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC | 37,056 | $0 M | 0.11% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 28,700 | $0 M | 0.08% | 0.01% | +2.8% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 34,966 | $0 M | 0.10% | 0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 25,385 | $0 M | 0.07% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 24,269 | $0 M | 0.07% | <0.01% | +29% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 24,832 | $0 M | 0.07% | 0.03% | +28% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 23,828 | $0 M | 0.07% | 0.02% | +2.3% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 19,094 | $0 M | 0.06% | <0.01% | +238% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 17,600 | $0 M | 0.05% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 15,234 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 15,099 | $0 M | 0.04% | <0.01% | −25% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 13,639 | $0 M | 0.04% | 0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 13,081 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 12,112 | $0 M | 0.04% | 0.02% | −27% | May 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 11,121 | $0 M | 0.03% | <0.01% | −0.7% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 11,062 | $0 M | 0.03% | 0.04% | −2.8% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 13,356 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 13,049 | $0 M | 0.04% | <0.01% | +9.8% | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 12,674 | $0 M | 0.04% | 0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 10,046 | $0 M | 0.03% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 9,530 | $0 M | 0.03% | 0.01% | −0.0% | May 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 9,229 | $0 M | 0.03% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 9,100 | $0 M | 0.03% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 8,141 | $0 M | 0.02% | 0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 8,050 | $0 M | 0.02% | 0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 9,180 | $0 M | 0.03% | <0.01% | +7.4% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 7,285 | $0 M | 0.02% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,136 | $0 M | 0.02% | 0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 5,937 | $0 M | 0.02% | 0.04% | +30% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 5,907 | $0 M | 0.02% | 0.05% | −15% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,770 | $0 M | 0.02% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 5,770 | $0 M | 0.02% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 5,684 | $0 M | 0.02% | 0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 4,852 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 5,250 | $0 M | 0.02% | 0.04% | — | Mar 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 4,167 | $0 M | 0.01% | 0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 3,997 | $0 M | 0.01% | 0.01% | +42% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,999 | $0 M | 0.01% | 0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 3,820 | $0 M | 0.01% | 0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 3,600 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 3,605 | $0 M | 0.01% | 0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 3,696 | $0 M | 0.01% | 0.01% | +1.6% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 3,631 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 3,193 | $0 M | <0.01% | 0.01% | +17% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 2,455 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 3,016 | $0 M | <0.01% | <0.01% | +4.0% | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 2,986 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 2,413 | $0 M | <0.01% | 0.03% | +28% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 2,091 | $0 M | <0.01% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,991 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,985 | $0 M | <0.01% | 0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,828 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 2,286 | $0 M | <0.01% | <0.01% | +42% | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,127 | $0 M | <0.01% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,341 | $0 M | <0.01% | <0.01% | −25% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1,198 | $0 M | <0.01% | 0.01% | +8.5% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,033 | $0 M | <0.01% | <0.01% | +50% | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 947 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 937 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 Vanguard Growth And Income FundWellington Management Company LLP | 800 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 698 | $0 M | <0.01% | <0.01% | −5.7% | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 605 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 585 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 564 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 400 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 317 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 161 | $0 M | <0.01% | <0.01% | +8.1% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 93 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at NeuroPace, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | R. Scott HuennekensDirector | Buyindirect | +12,500 | $8.293 | $104 K | 12,500 | Form 4 |
| filed | Joel BeckerCHIEF EXECUTIVE OFFICER, Director | Buy | +11,891 | $8.350 | $99 K | 149,891 | Form 4 |
| filed | Patrick F. WilliamsChief Financial Officer | Buy | +11,891 | $8.338 | $99 K | 79,399 | Form 4 |
| filed | Martha MorrellCHIEF MEDICAL OFFICER | Shares withheld for tax | -335 | $13.97 | $5 K | 51,357 | Form 4 |
| filed | Patrick F. WilliamsChief Financial Officer | Shares withheld for tax | -1,162 | $14.28 | $17 K | 67,508 | Form 4 |
| filed | Joel BeckerCHIEF EXECUTIVE OFFICER, Director | Shares withheld for tax | -1,310 | $14.75 | $19 K | 138,000 | Form 4 |
| filed | Martha MorrellCHIEF MEDICAL OFFICER | Shares withheld for tax | -358 | $14.13 | $5 K | 51,692 | Form 4 |
| filed | Joel BeckerCHIEF EXECUTIVE OFFICER, Director | Shares withheld for tax | -1,126 | $14.13 | $16 K | 139,310 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: NeuroPace, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-2.6 reverse split ; 1-for-100 reverse split
| Dividend, quarter | Per share | |
|---|---|---|
| Q1 2026 | $0.000 | |
| Q1 2025 | $0.000 |
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0M |
| Q2 2026 | Q2 2026 | $0M |
| Q1 2026 | Q1 2026 | $0M |
| Q4 2025 | Q4 2025 | $0M |
| Q3 2025 | Q3 2025 | $0M |
| Q2 2025 | Q2 2025 | $0M |
| Q1 2025 | Q1 2025 | $49.5M |
| Q4 2024 | Q4 2025 | $0M |
| Q3 2024 | Q3 2025 | $0M |
| Q2 2024 | Q2 2025 | $0M |
| Q1 2024 | Q1 2025 | $0M |
Fails to deliver
- : 531 shares at $14.15
- : 2 shares at $14.74
- : 28 shares at $14.64
- : 97 shares at $14.88
- : 29 shares at $13.70
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
NeuroPace, Inc. scorecard#
Passes 7 of the 18 checks that could be worked out: strongest in growth (5 of 6), weakest in shareholder returns (0 of 3). Fiscal year 2025; market cap of Sep 18, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-09-18, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-09-18, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-09-18, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-09-18, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-09-18, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-09-18, more than 60 days ago.
Growth5 of 6
- ✓Revenue grew in the newest year25.1%Revenue up 25.1% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years30.0%30.0% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median30.0%30.0% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-0.66 vs -0.93Diluted EPS -0.66 in fiscal 2025 against -0.93 the year before (report's currency).
- ✓Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$24 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-16.3%-16.3% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-158.7%-158.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-16.3%-16.3% in fiscal 2025 against -89.6% in 2022.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities5.3×Current ratio 5.28 at the end of fiscal 2025.
- ✗Debt below equity3.1×Debt to equity 3.09 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-2.64Z-score -2.64 (distress zone) for fiscal 2025.
Shareholder returns0 of 3
- ✗Pays a dividendNoNo dividends in fiscal 2025.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year12.3%Diluted shares up 12.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-09-18, more than 60 days ago.
- ✗Free cash flow covers dividends and buybacks-$11 MFree cash flow -$11 M against $50 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from NeuroPace, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -16.3% | -8.2% | |
| Net margin | -21.5% | -10.4% | |
| Return on equity | -158.7% | -16.8% | |
| Revenue growth, 3 years a year | 30.0% | 10.8% | |
| Revenue growth | 25.1% | 10.4% | |
| Debt to equity | 3.09× | 0.64× |
5of 9on the Piotroski tests of financial strength
- Net loss of $21 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$11 million.
- The share count rose 12.3% in the year.
- Revenue has grown 5 years in a row.
NeuroPace, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 100+25.1%100% | 80+22.1%100% | 65+43.7%100% | 46+0.7%100% | 45+9.8%100% | 41—100% | |
| Cost of revenue | 23+9.3%22.8% | 21+20.4%26.1% | 17+32.8%26.4% | 13+10.9%28.6% | 12+8.1%26.0% | 11—26.4% | |
| Gross profit | 77+30.7%77.2% | 59+22.8%73.9% | 48+48.1%73.6% | 32−2.8%71.4% | 33+10.4%74.0% | 30—73.6% | |
| Research and development | 28+17.9%27.9% | 24+13.8%29.6% | 21−5.3%31.8% | 22+20.5%48.2% | 18+16.0%40.3% | 16—38.2% | |
| Selling, general and administrative | — | 57+4.7%71.5% | 55+6.2%83.3% | 51+31.8%113% | 39+41.0%86.2% | 28—67.2% | |
| Selling and marketing | 47+17.4%46.6% | 40—49.6% | — | — | — | — | |
| General and administrative | 19+9.5%19.1% | 17—21.8% | — | — | — | — | |
| Operating expenses | 94+15.9%93.6% | 81+7.3%101% | 75+2.7%115% | 73+28.2%161% | 57+32.0%127% | 43—105% | |
| Operating income | −16—−16.3% | −22—−27.1% | −27—−41.5% | −41—−89.6% | −24—−52.5% | −13—−31.7% | |
| Interest and finance income | 2.8−6.9%2.8% | 3.0−0.9%3.8% | 3.1+93.3%4.7% | 1.6+252%3.5% | 0.4+993%1.0% | 0.0—0.1% | |
| Interest expense and finance costs | 7.5−15.2%7.5% | 8.8+3.3%11.0% | 8.5+13.1%13.0% | 7.5+1.6%16.5% | 7.4−35.5%16.4% | 11—27.9% | |
| Other non-operating income (expense) | −0.5−260%−0.5% | 0.3—0.4% | −0.3—−0.5% | −0.3—−0.7% | −5.4−2568%−11.9% | 0.2—0.5% | |
| Income tax | 0—0.0% | — | — | — | — | — | |
| Net income attributable to shareholders | −21—−21.5% | −27—−34.0% | −33—−50.4% | −47—−103% | −36—−79.9% | −24—−59.0% | |
| Earnings per share, basic | -0.66—— | -0.93—— | -1.27—— | -1.91—— | -2.17—— | -117.85—— | |
| Earnings per share, diluted | -0.66—— | -0.93—— | -1.27—— | -1.91—— | -2.17—— | -117.85—— | |
| Shares, weighted average (basic) | 33+12.3%— | 29+12.7%— | 26+5.1%— | 25+48.1%— | 17+8039%— | 0.2—— | |
| Shares, weighted average (diluted) | 33+12.3%— | 29+12.7%— | 26+5.1%— | 25+48.1%— | 17+8039%— | 0.2—— | |
| Dividends per share | 0.00—— | 0.00—— | 0.00—— | — | — | — | |
| Balance sheet | |||||||
| Cash and cash equivalents | 22+61.5%20.5% | 13−25.6%14.2% | 18+173%16.8% | 6.6−65.6%5.8% | 19−27.3%14.4% | 26—47.2% | |
| Short-term investments | 39+0.1%37.3% | 39−18.7%41.5% | 48−31.6%45.0% | 71−26.5%62.1% | 96+725%72.2% | 12—20.9% | |
| Receivables | 13r15+0.7%12.3% | 13+4.4%13.6% | 12+64.6%11.4% | 7.5+5.5%6.6% | 7.1−15.5%5.3% | 8.4—15.0% | |
| Inventory | 15r17+11.1%14.1% | 13+19.3%14.1% | 11+15.5%10.4% | 9.7+24.2%8.5% | 7.8+13.2%5.9% | 6.9—12.3% | |
| Other current assets | 1.4−38.9%1.4% | 2.4−14.1%2.5% | 2.7−12.0%2.5% | 3.1+34.2%2.7% | 2.3+96.7%1.7% | 1.2—2.1% | |
| Current assets | 94+15.7%89.1% | 81−12.3%85.9% | 93−5.1%86.1% | 98−26.4%85.6% | 133+143%99.4% | 55—97.5% | |
| Property, plant and equipment | 1.1+6.9%1.1% | 1.1+4.9%1.1% | 1.0−5.7%0.9% | 1.1+76.5%0.9% | 0.6+17.1%0.5% | 0.5—0.9% | |
| Right-of-use (leased) assets | 10−14.4%9.6% | 12−11.7%12.5% | 13−9.7%12.5% | 15—13.0% | 0—0.0% | — | |
| Total assets | 106+11.5%100% | 95−12.1%100% | 108−5.7%100% | 114−14.6%100% | 134+139%100% | 56—100% | |
| Accounts payable | 1.8r2.2−39.9%1.7% | 3.0+26.7%3.1% | 2.3+8.6%2.2% | 2.1+55.8%1.9% | 1.4+45.2%1.0% | 0.9—1.7% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 2.0—3.7% | |
| Current liabilities | 18+17.5%16.9% | 15−6.6%16.0% | 16+47.9%15.1% | 11+18.0%9.6% | 9.3−3.1%7.0% | 9.6—17.1% | |
| Long-term debt | 59−1.1%55.8% | 60+4.5%62.9% | 57+7.6%52.9% | 53+6.2%46.4% | 50−1.9%37.3% | 51—90.8% | |
| Lease liabilities (non-current) | 9.8−17.7%9.3% | 12−13.5%12.6% | 14−10.5%12.8% | 15—13.5% | 0—0.0% | — | |
| Total liabilities | 87−0.1%82.0% | 87−0.4%91.5% | 87+9.7%80.8% | 79+32.1%69.5% | 60−3.7%45.0% | 62—111% | |
| Retained earnings | −552—−523% | −531—−561% | −504—−468% | −471—−413% | −424—−317% | −388—−693% | |
| Shareholders' equity | 19+138%18.0% | 8.0−61.2%8.5% | 21−40.6%19.2% | 35−52.7%30.5% | 74—55.0% | −148—−264% | |
| Total liabilities and equity | 106+11.5%100% | 95−12.1%100% | 108−5.7%100% | 114−14.6%100% | 134+139%100% | 56—100% | |
| Shares outstanding | 34+11.4%— | 30+8.3%— | 28+11.1%— | 25+2.4%— | 24+7685%— | 0.3—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 11+7.8%11.1% | 10+7.6%12.9% | 9.6+14.5%14.6% | 8.3+94.7%18.3% | 4.3+211%9.5% | 1.4—3.4% | |
| Cash from operating activities | −11—−11.0% | −18—−22.5% | −20—−30.1% | −37—−81.0% | −25—−54.4% | −22—−52.5% | |
| Capital expenditure | −0.3—−0.3% | −0.3—−0.4% | −0.2—−0.3% | −0.6—−1.3% | −0.4—−0.8% | −0.1—−0.2% | |
| Cash from investing activities | −0.3−104%−0.3% | 9.0−60.9%11.3% | 23−3.2%35.2% | 24—52.3% | −85—−189% | −11—−26.2% | |
| Debt issued | — | — | — | — | 0−100%0.0% | 54—131% | |
| Debt repaid | — | — | — | 0—0.0% | −4.1—−9.1% | −42—−102% | |
| Shares bought back | −50—−49.6% | 0—0.0% | — | — | — | — | |
| Cash from financing activities | 20+353%19.6% | 4.3−46.8%5.4% | 8.1+1559%12.4% | 0.5−99.5%1.1% | 103+86.4%227% | 55—134% | |
| Change in cash | 8.3—8.3% | −4.6−140%−5.8% | 11—17.5% | −13—−27.6% | −7.4−133%−16.5% | 23—55.0% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 107+23.0%100% | 23−1.1%100% | 23+17.1%100% | 22−2.0%100% | 39r27*+80.8%100% | 23r27+10.9%100% | 20r24+1.3%100% | 23+24.3%100% | 21*+19.2%100% | 21—100% | 19—100% | 18—100% | 18*—100% | |
| Cost of revenue | 24+32.1%22.2% | 3.6−13.1%15.7% | 3.9+19.2%17.2% | 4.0−22.4%18.2% | 12r6.0*+129%31.2% | 4.2r6.2−25.9%17.9% | 3.3r5.4−35.8%16.9% | 5.2+8.4%23.0% | 5.3*+18.2%24.6% | 5.6—26.8% | 5.1—26.6% | 4.8—26.4% | 4.5*—24.8% | |
| Gross profit | 83+20.6%77.8% | 19+1.6%84.3% | 19+16.6%82.8% | 18+4.1%81.8% | 27r21*+65.0%68.8% | 19r21+24.3%82.1% | 16r18+14.7%83.1% | 17+30.0%77.0% | 16*+19.5%75.4% | 15—73.2% | 14—73.4% | 13—73.6% | 14*—75.2% | |
| Research and development | 27+1.4%25.5% | 6.2−6.2%26.7% | 6.9+0.8%30.2% | 7.2−3.4%32.6% | 7.0*+16.1%18.1% | 6.6+14.3%28.2% | 6.8+12.9%35.1% | 7.4+28.6%33.0% | 6.1*+12.5%28.2% | 5.8—27.3% | 6.1—31.5% | 5.8—31.9% | 5.4*—29.9% | |
| Selling, general and administrative | — | — | — | — | — | — | — | 15−0.4%66.8% | 14*+4.3%64.2% | 14—66.0% | 14—74.3% | 15—83.3% | 13*—73.4% | |
| Selling and marketing | 48+6.9%44.5% | 11−7.1%48.3% | 12+5.5%53.1% | 12+5.3%52.5% | 13r11*+27.2%32.6% | 12r13+21.1%51.5% | 11r12+17.8%58.9% | 11—48.9% | 10.0*—46.4% | 9.9—47.1% | 9.8—50.7% | — | — | |
| General and administrative | 18−0.4%17.3% | 4.2−8.2%18.2% | 5.0−17.2%22.0% | 4.8+19.7%22.0% | 4.4*+14.1%11.3% | 4.6+15.4%19.7% | 6.1+33.6%31.1% | 4.0—18.0% | 3.8*—17.9% | 4.0—18.9% | 4.5—23.6% | — | — | |
| Operating expenses | 93+3.7%87.3% | 22−7.1%93.3% | 24−1.4%105% | 24+5.0%107% | 24r22*+21.3%62.0% | 23r24+18.0%99.3% | 24r25+19.8%125% | 22+7.7%99.8% | 20*+6.7%92.4% | 20—93.4% | 20—106% | 21—115% | 19*—103% | |
| Operating income | −10—−9.5% | −2.1—−9.0% | −5.1—−22.5% | −5.6—−25.2% | 2.6r−1.8*—6.8% | −4.0r−2.6—−17.2% | −8.2r−6.8—−42.0% | −5.1—−22.9% | −3.7*—−17.0% | −4.2—−20.1% | −6.2—−32.4% | −7.5—−41.6% | −5.1*—−28.0% | |
| Interest and finance income | 2.2−21.8%2.1% | 0.5−23.4%2.2% | 0.5−27.2%2.3% | 0.6−28.8%2.6% | 0.6*−6.3%1.6% | 0.7−11.5%2.9% | 0.7−5.8%3.7% | 0.8−4.1%3.5% | 0.7*−17.2%3.2% | 0.8—3.6% | 0.8—4.0% | 0.8—4.6% | 0.8*—4.6% | |
| Interest expense and finance costs | 6.2−22.7%5.8% | 1.6−4.9%6.8% | 1.5−25.3%6.7% | 1.5−29.4%6.9% | 1.6*−27.0%4.1% | 1.6−24.6%7.0% | 2.1−4.9%10.6% | 2.2−4.7%9.6% | 2.2*−2.0%10.2% | 2.2—10.4% | 2.2—11.2% | 2.3—12.5% | 2.2*—12.4% | |
| Other non-operating income (expense) | −0.4—−0.3% | −0.2−300%−0.7% | −0.0—−0.2% | −0.2—−0.7% | 0*—0.0% | 0.1−62.6%0.4% | −0.5−505%−2.5% | −0.1−261%−0.4% | −0.1*−132%−0.4% | 0.2—1.0% | 0.1—0.6% | 0.1—0.3% | 0.3*—1.5% | |
| Income tax | — | — | — | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | 0—0.0% | 0—0.0% | 0—0.0% | — | |
| Income from continuing operations | — | −3.3—−14.3% | −6.2—−27.2% | — | — | −4.9—−21.1% | −10—−51.4% | — | — | — | — | — | — | |
| Income from discontinued operations | — | 0−100%0.0% | 0−100%0.0% | — | — | 1.4—6.1% | 1.4—7.0% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −19—−17.7% | −3.3—−14.3% | −6.2—−27.2% | −6.7—−30.3% | −2.7*—−7.0% | −3.5—−15.0% | −8.7—−44.4% | −6.6—−29.3% | −5.3*—−24.5% | −5.5—−25.9% | −7.5—−39.0% | −8.9—−49.2% | −6.2*—−34.4% | |
| Earnings per share, basic | — | -0.10—— | -0.18—— | -0.20—— | — | -0.11—— | -0.26—— | -0.21—— | — | -0.19—— | -0.26—— | -0.32—— | — | |
| Earnings per share, diluted | — | -0.10—— | -0.18—— | -0.20—— | — | -0.11—— | -0.26—— | -0.21—— | — | -0.19—— | -0.26—— | -0.32—— | — | |
| Shares, weighted average (basic) | 34+3.7%— | 34+3.7%— | 34+3.8%— | 34+7.1%— | — | 33+12.5%— | 33+13.9%— | 31+11.3%— | — | 29—— | 29—— | 28—— | — | |
| Shares, weighted average (diluted) | 34+3.7%— | 34+3.7%— | 34+3.8%— | 34+7.1%— | — | 33+12.5%— | 33+13.9%— | 31+11.3%— | — | 29—— | 29—— | 28—— | — | |
| Dividends per share | — | — | — | 0.00—— | — | — | — | 0.00—— | — | — | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 10—10.8% | 10−50.4%10.8% | 13−45.1%12.9% | 15−45.3%14.9% | 22+61.5%20.5% | 21+33.9%19.3% | 23+78.0%21.5% | 27+108%24.5% | 13−25.6%14.2% | 15—16.0% | 13—13.6% | 13—13.1% | 18—16.8% | |
| Short-term investments | 39—41.1% | 39−0.9%41.1% | 39−0.3%40.4% | 39−0.1%39.6% | 39+0.1%37.3% | 39−4.9%36.7% | 39−8.0%37.0% | 39−14.6%35.6% | 39−18.7%41.5% | 41—43.0% | 43—45.2% | 46—46.5% | 48—45.0% | |
| Receivables | 14—15.1% | 14−4.4%15.1% | 15+10.2%15.4% | 15−4.2%15.0% | 13r15+0.7%12.3% | 15+29.2%13.9% | 14+20.6%12.8% | 15+32.7%14.0% | 13+4.4%13.6% | 12—12.0% | 11—11.9% | 12—11.8% | 12—11.4% | |
| Inventory | 19—19.8% | 19+3.7%19.8% | 18+10.8%18.7% | 17+22.9%16.9% | 15r17+11.1%14.1% | 18+50.1%16.9% | 16+43.9%15.4% | 14+19.0%12.3% | 13+19.3%14.1% | 12—12.5% | 11—12.0% | 11—11.5% | 11—10.4% | |
| Other current assets | 2.2—2.4% | 2.2−0.4%2.4% | 1.5−14.6%1.5% | 1.5−31.2%1.5% | 1.4−38.9%1.4% | 2.2+6.0%2.1% | 1.7−18.4%1.6% | 2.2−2.7%2.0% | 2.4−14.1%2.5% | 2.1—2.2% | 2.1—2.2% | 2.3—2.3% | 2.7—2.5% | |
| Current assets | 85—89.2% | 85−11.3%89.2% | 86−8.1%88.9% | 87−10.8%87.9% | 94+15.7%89.1% | 95+15.4%88.9% | 94+16.8%88.3% | 97+15.7%88.5% | 81−12.3%85.9% | 83—85.8% | 80—85.0% | 84—85.2% | 93—86.1% | |
| Property, plant and equipment | 1.2—1.2% | 1.2+5.1%1.2% | 1.2+7.5%1.3% | 1.3+10.6%1.3% | 1.1+6.9%1.1% | 1.1+6.4%1.0% | 1.2+15.8%1.1% | 1.2+10.7%1.1% | 1.1+4.9%1.1% | 1.0—1.1% | 1.0—1.1% | 1.0—1.1% | 1.0—0.9% | |
| Right-of-use (leased) assets | 8.7—9.2% | 8.7−17.4%9.2% | 9.2−16.3%9.5% | 9.7−15.3%9.8% | 10−14.4%9.6% | 11−13.6%9.9% | 11−12.9%10.4% | 11−12.3%10.4% | 12−11.7%12.5% | 12—12.7% | 13—13.4% | 13—13.2% | 13—12.5% | |
| Total assets | 95—100% | 95−11.6%100% | 97−8.6%100% | 99−10.3%100% | 106+11.5%100% | 107+11.4%100% | 106+12.4%100% | 110+11.5%100% | 95−12.1%100% | 96—100% | 94—100% | 99—100% | 108—100% | |
| Accounts payable | 3.2—3.4% | 3.2−29.4%3.4% | 4.2−11.0%4.3% | 4.5+11.5%4.6% | 1.8r2.2−39.9%1.7% | 4.6+113%4.3% | 4.7+106%4.4% | 4.0+23.8%3.7% | 3.0+26.7%3.1% | 2.2—2.2% | 2.3—2.4% | 3.3—3.3% | 2.3—2.2% | |
| Current liabilities | 16—17.0% | 16−18.0%17.0% | 17+1.7%18.0% | 16+9.9%16.3% | 18+17.5%16.9% | 20+32.7%18.3% | 17+36.2%16.2% | 15+12.2%13.3% | 15−6.6%16.0% | 15—15.3% | 13—13.3% | 13—13.3% | 16—15.1% | |
| Long-term debt | 59—62.4% | 59+0.7%62.4% | 59+0.7%60.8% | 59−1.3%59.7% | 59−1.1%55.8% | 59−0.9%54.8% | 59−0.7%55.2% | 60+3.0%54.3% | 60+4.5%62.9% | 59—61.5% | 59—62.5% | 58—58.7% | 57—52.9% | |
| Lease liabilities (non-current) | 8.1—8.5% | 8.1−22.4%8.5% | 8.7−20.7%8.9% | 9.3−19.1%9.4% | 9.8−17.7%9.3% | 10−16.5%9.7% | 11−15.4%10.3% | 11−14.4%10.4% | 12−13.5%12.6% | 12—12.9% | 13—13.7% | 13—13.5% | 14—12.8% | |
| Total liabilities | 83—87.9% | 83−6.1%87.9% | 85−1.8%87.7% | 84−1.7%85.4% | 87−0.1%82.0% | 89+2.6%82.7% | 87+2.6%81.7% | 86+1.7%78.0% | 87−0.4%91.5% | 86—89.8% | 85—89.5% | 85—85.5% | 87—80.8% | |
| Retained earnings | −569—−600% | −569—−600% | −565—−583% | −559—−565% | −552—−523% | −550—−513% | −546—−515% | −538—−488% | −531—−561% | −526—−546% | −520—−551% | −513—−519% | −504—−468% | |
| Shareholders' equity | 11—12.1% | 11−37.9%12.1% | 12−38.9%12.3% | 14−40.4%14.6% | 19+138%18.0% | 19+88.5%17.3% | 19+96.6%18.3% | 24+69.2%22.0% | 8.0−61.2%8.5% | 9.8—10.2% | 9.9—10.5% | 14—14.5% | 21—19.2% | |
| Total liabilities and equity | 95—100% | 95−11.6%100% | 97−8.6%100% | 99−10.3%100% | 106+11.5%100% | 107+11.4%100% | 106+12.4%100% | 110+11.5%100% | 95−12.1%100% | 96—100% | 94—100% | 99—100% | 108—100% | |
| Shares outstanding | 34—— | 34+3.5%— | 34+3.7%— | 34+3.5%— | 34+11.4%— | 33+11.8%— | 33+13.4%— | 33+14.0%— | 30+8.3%— | 30—— | 29—— | 29—— | 28—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 9.6−13.2%9.0% | 2.4−7.5%10.5% | 2.3−28.7%10.1% | 2.3−13.3%10.3% | 2.6*+0.2%6.7% | 2.6+1.4%11.3% | 3.2+26.7%16.6% | 2.6+3.4%11.7% | 2.6*+10.4%12.1% | 2.6—12.3% | 2.5—13.2% | 2.5—14.0% | 2.4*—13.1% | |
| Cash from operating activities | −12—−11.3% | −2.8*—−12.0% | −3.9*—−17.1% | −5.9—−26.7% | 0.5*—1.3% | −1.9*—−8.3% | −2.1*—−10.7% | −7.5—−33.2% | −4.8*—−22.3% | −1.7*—−8.2% | −3.9*—−20.3% | −7.5—−41.5% | −3.3*—−18.5% | |
| Capital expenditure | −0.4—−0.3% | −0.0*—−0.1% | −0.1*—−0.5% | −0.1—−0.5% | −0.1*—−0.2% | −0.0*—−0.1% | −0.2*—−0.9% | −0.0—−0.2% | −0.0*—−0.2% | −0.1*—−0.5% | −0.1*—−0.3% | −0.1—−0.6% | −0.0*—−0.2% | |
| Cash from investing activities | −0.4−121%−0.3% | −0.0*—−0.1% | −0.1*—−0.5% | −0.1—−0.5% | −0.1*−105%−0.2% | −0.0*−102%−0.1% | −0.2*−105%−0.9% | −0.0−102%−0.2% | 2.0*−43.5%9.1% | 1.4*—6.6% | 3.2*—16.8% | 2.4—13.2% | 3.5*—19.3% | |
| Shares bought back | 0—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −50—−220% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | — | |
| Cash from financing activities | 2.1−89.3%2.0% | 0.5*—2.1% | 1.2*—5.2% | −0.2−101%−0.8% | 0.6*−25.1%1.6% | −0.2*−108%−1.0% | −1.9*−475%−9.8% | 21+29217%93.7% | 0.8*−89.7%4.0% | 2.9*—13.8% | 0.5*—2.6% | 0.1—0.4% | 8.2*—45.6% | |
| Change in cash | −10−297%−9.6% | −2.3*—−10.0% | −2.9*—−12.5% | −6.2−146%−28.0% | 1.0*—2.7% | −2.2*−186%−9.5% | −4.2*—−21.3% | 14—60.3% | −2.0*−124%−9.3% | 2.6*—12.2% | −0.2*—−0.8% | −5.1—−27.9% | 8.3*—46.3% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What NeuroPace, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- Non-US(total)$1 M0.9%+350%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at NeuroPace, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 2 · Agreement ended 1 · New debt 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by NeuroPace, Inc.#
$130 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.
- Medicare/Medicaid3 reports
Lobbying firms hired in 2025
LMH STRATEGIC SOLUTIONS $130 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $90 K | — | 3 |
| 2025 | $130 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “NeuroPace, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at NeuroPace, Inc.#
1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $91 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Field Clinical EngineerBiomedical Engineers | 1 | $91 K |
Where: Long Beach, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2022 | 1 | 1 | $91 K | 1 |
| FY2021 | 1 | 1 | $155 K | 1 |
| FY2020 | 1 | 1 | $106 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as NeuroPace, Inc.
Discuss NeuroPace, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
NeuroPace, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $23 million (down 1% from a year earlier) and a net loss of $3 million.
- Mutual funds: 93 funds hold $73 millionautomatic update · Jul 31, 2026
93 mutual funds in 1 country hold shares of NeuroPace, Inc. worth $73 million, about 13.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 47 funds added shares and 26 sold; on balance they bought $1 million. Share splits are not counted as trading.
How NeuroPace, Inc. compares in Medical Devices
- Market cap$487 M · higher than 49% of 142
- Revenue$100 M · higher than 41% of 155
- Net margin-18.4% · higher than 36% of 144
- Revenue growth25.1% · higher than 78% of 104
- Price / sales4.8× · lower than 31% of 96
- Price / book25.6× · lower than 5% of 99
- FCF yield-2.3% · higher than 48% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| NeuroPace, Inc.🇺🇸 | $487 M | — | -18.4% | +25.1% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Delcath Systems, Inc.$500 M
- 908 Devices Inc.$503 M
- Sight Sciences, Inc.$448 M
- AK Medical Holdings Limited$537 M
- Tactile Systems Technology, Inc.$545 M
- OrthoPediatrics Corp.$573 M
Sources and freshness
- Market cap:
- Sep 18, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at NeuroPace, Inc.? Verify and update this profile — free
Show NeuroPace, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.